Cathepsin L, target in cancer treatment?

Jacqueline M. Lankelma, Daniëlle M. Voorend, Temo Barwari, Joris Koetsveld, Anne H. van der Spek, Alexander P. N. A. de Porto, Geeske van Rooijen, Cornelis J. F. van Noorden

Research output: Contribution to journalReview articleAcademicpeer-review

139 Citations (Scopus)

Abstract

Cathepsin L a cysteine protease, is considered to be a potential therapeutic target in cancer treatment. Proteases are involved in the development and progression of cancer. Inhibition of activity of specific proteases may slow down cancer progression. In this review, we evaluate recent studies on the inhibition of cathepsin L in cancer. The effects of cathepsin L inhibition as a monotherapy on apoptosis and angiogenesis in cancer are ambiguous. Cathepsin L inhibition seems to reduce invasion and metastasis, but there is concern that selective cathepsin L inhibition induces compensatory activity by other cathepsins. The combination of cathepsin L inhibition with conventional chemotherapy seems to be more promising and has yielded more consistent results. Future research should be focused on the mechanisms and effects of this combination therapy. (C) 2009 Elsevier Inc. All rights reserved
Original languageEnglish
Pages (from-to)225-233
JournalLife sciences
Volume86
Issue number7-8
DOIs
Publication statusPublished - 2010

Cite this